Nitric oxide synthase inhibition prevents acute quinolinate-induced striatal neurotoxicity

Neurochemical Research

Volumn 23, Issue 10, 1998, Pages 1297-1302

  Pérez Severiano, Francisca ^a   Escalante, Bruno ^b   Ríos, Camilo ^a,c  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

Lipid peroxidation; Neurotoxicity; Nitric oxide; Quinolinic acid; Striatum

Indexed keywords

ARGININE; CALCIUM; CITRULLINE; DIZOCILPINE; EXCITOTOXIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; QUINOLINIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; ENZYME INHIBITION; HUNTINGTON CHOREA; INTRAVENOUS DRUG ADMINISTRATION; LIPID PEROXIDATION; MALE; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ANIMALS; CORPUS STRIATUM; ENZYME INHIBITORS; MALE; MOTOR ACTIVITY; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; QUINOLINIC ACID; RATS; RATS, WISTAR;

ANIMALIA;

EID: 0031763724     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020700401678     Document Type: Article

References (47)

1. Perkins, M. N., and Stone, T. W. 1983. Pharmacology and regional variations of quinolinic acid evoked excitations in the rat central nervous system. J. Pharmacol. Exp. Ther. 226:551-557.
2. Schwarcz, R., Whetsell, W. O., and Mangano, R. M. 1983. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science. 219:316-318.
3. Beal, M. F., Kowall, N. W., Ellison, D. W., Mazurek, M. F., Schwarcz, K. J., and Martin, J. B. 1986. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 321:168-171.
4. Reynolds, G. P., Pearson, S. J., Halket, J., and Sandier, M. 1988. Brain quinolinic acid in Huntington's disease. J. Neurochem. 50: 1959-1960.
5. Stone, T. W. 1993. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 45(3):309-379.
6. Wolfensberger, M., Amsler, U., Cuenod, M., Foster, A. C., Whetsell, W. O., and Schwarcz, R. 1983. Identification of quinolinic acid in rat and human brain tissue. Neurosci. Lett. 41:247-252.
7. Moroni, F., Lombardi, G., Moneti, G., and Aldino, G. 1984. The excitotoxin quinolinic acid is present in the brain of several mammals and it's cortical contents increases during the aging process. Neurosci. Lett. 47:51-55.
8. Beal, M. F., Matson, W. R., Swartz, K. J., Gamache, P. H., and Bird, E. D. 1990. Kynurenine pathway measurements in Huntington's disease striatum: Evidence for reduced formation of kynurenic acid. J. Neurochem. 55:1327-1339.
9. Albin, R. L., Young, A. B., Penney, J. B., Handelin, B., Balfour, R., et al. 1990. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's diseases. N. Engl. J. Med. 322:1293-1298.
10. Heyes, M. P., Saito, K., Crowlwy, J. S., Davis, L. E., Demitrack, M. A., et al. 1992. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory disease. Brain. 115:1249-1273.
11. Ríos, C., and Santamaría, A. 1991. Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem. Res. 16(10):1139-1143.
12. Santamaria, A., and Rios, C. 1993. MK-801, an N-methyl-D-aspartate receptor antagonist, blocks quinolinic acid-induced lipid peroxidation in rat corpus striatum. Neurosci. Lett. 159:51-54.
13. Susel, Z., Engber, T. M., and Chase, T. N. 1989. Behavioral evaluation of the anti-excitotoxic properties of MK-801: comparison with neurochemical measurements. Neurosci. Lett. 104:125-129.
14. Schmidt, W., Wolf, G., Calka, J., and Schmidt, H. H. H. W. 1995. Evidence for bidirectional changes in nitric oxide synthase activity in the rat striatum after excitotoxically (quinolinic acid) induced degeneration. Neuroscience. 67(2):345-356.
15. Moncada, S., Palmer, R. M. J., and Higgs, E. A. 1991. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol. Rev. 43:109-143.
16. Chapman, P. F., Atkins, C. M., Allen, M. T., et al. 1992. Inhibition of nitric oxide synthesis impairs two different forms of learning. NeuroReport. 3:567-570.
17. O'Dell, T. J., Hawkins, R. D., Kandel, E. R., and Arancio, O. 1991. Test of the roles of two diffusable substances in long term potentiation: Evidence for nitric oxide as a possible early retrograde messenger. Proc. Natl. Acad. Sci. U.S.A. 88:1185-1289.
18. Rubbo, H., Radi, R., Trujillo, M., Telleri, R., Kalyanaraman, B., et. al. 1994. Nitric oxide regulation of Superoxide and peroxinitrite-depend lipid peroxidation. J. Biol. Chem. 269(42):26066-26091.
19. Lipton, S. A., Choi, Y. B., Pan, Z. H., Lei, S. Z., Chen, H. S. V., et.al. 1993. A redox based mechanism for the neuroprotective ans neurodestructive effects of nitric oxide and related nitroso compounds. Nature. 364:626-632.
20. Lipton, S. A., and Stamler, J. S. 1994. Actions of redox congeners of nitric oxide at the NMDA receptor. Neuropharmacol. 33 (11): 1229-1233.
21. Garthwaite, G., and Garthwite, J. 1988. Cyclic GMP and cell death in rat cerebelar slices. Neuroscience. 26:321-326.
22. Dawson, V. L., Dawson, T. M., London, E. D., Bredt, D. S., and Snyder, S. H. 1991. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc. Natl. Acad. Sci. USA. 88:6368-6371.
23. Garthwaite, J. 1991. Glutamate, nitric oxide and cell-cell signaling in the neurons system. Trend Neurosci. 14:60-67.
24. Kiedrowski, L., Costa, E., Wroblewski, J. T. 1992. In vitro interaction between cerebelar astrocytes and granule cells: a putative role for nitric oxide. Neurosci. Lett. 135:59-61.
25. Paxinos, G., and Watson, G. 1984. The rat brain in stereotaxic coordinates, Sydney. Academic Press.
26. Giordano, M., Ford, L. M., Braucman, J. L., Norman, A. B., and Sanberg, P. R. 1990. MK-801 Prevents quinolinic acid-induced behavioral deficits and neurotoxicity in the striatum. Brain Res. Bull. 24:313-319.
27. G-nitro-arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro. Br. J. Pharmacol. 99:408-412.
28. Bredt, D. S., and Snyder, S. H. 1990. Isolation of nitric oxide synthase, a calmodulin-requiring enzyme. Proc. Natl. Acad. Sci. USA. 87:682-685.
29. Bradford, M. M. 1976. A rapid and sensitive method for the quantification of protein dye binding. Anal. Biochem. 72:248-254.
30. ++ injection. J. Neurochem. 42:976-979.
31. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. 1951. Protein measurement with the folin-phenol reagent. J. Biol. Chem. 193:265-275.
32. Schwarcz, R., Fuxe, K., Agnati, L. F., Hockfelt, T., and Coyle, J. T. 1979. Rotational behavior in rats with unilateral striatal kainic lesions: a behavioral model for studies on intact dopamine receptors. Brain Res. 170:485-495.
33. Fisher, R. S. 1991. Introduction to the excitatory amino acid system. Epilepsy. 10:3-8.
34. Fisher, R. S. 1991. Glutamate and epilepsy. Neurotransmitters Epilepsy. 11:131-45.
35. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature. 349:414-18.
36. Lipton, S. A., Sucher, N. J., Kaiser, P. K., and Dreyer, E. B. 1991. Synergistic effects of HIV coat protein and NMDA receptor-mediated neurotoxicity. Neuron. 7:111-18.
37. Jansen, K. L. R., Faull, R. L. M., Dragunow, M., and Synek, B. L. 1990. Alzheimer's disease-changes in hippocampal N-methyl-D-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and apioid receptors an autoradiographic study. Neurosci. 39:613-27.
38. Choi, D. W. 1988. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1:623-34.
39. Simonian, N. A., and Coyle, J. T. 1996. Oxidative stress in neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 36:83-106.
40. Heyes, M. P., Brew, B. J., Martin, A., Price, R. W., and Salazar A. M. 1991. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurologic status. Ann. Neurol. 29:202-209.
41. Heyes, M. P. 1996. The kinurenine pathway and neurologic disease. Therapeutic strategies. Adv. Exp. Med. Biol. 398:125-9.
42. + channels, glutamate release and NMDA receptors mediates delayed neurodegeneration through nitric oxide formation. Neurosci. Res. 16(16):5004-13.
43. Park, S. K., Grzybicki D., Lin, H. L., and Murphy, S. 1994. Modulation of inducible nitric oxide synthase expression in astroglial cells. Neuropharmacol. 33(11):1419-1423.
44. Moncada, S., Herman, A. G., and Vanhoutte, P. M. 1987. Endothelium-derived relaxing factor is identified as nitric oxide. Trends Pharmacol. Sci. 8:365-367.
45. Galasso, J. M., Bazzett, T. J., Becker, J. B., and Albin, R. L. 1995. Synergistic effect of intraestriatal coadministration of L-NAME and quinolinic acid. Neuro Report. 6:1505-1608.
46. Globus, M. Y. -T., Prado, R., Sanchez-Ramos, J., Zhao, Weizhao., Dietrich, W. D., Busto, R., and Ginsberg, M. D. 1995. A dual Role for nitric oxide in NMDA-mediated toxicity in vivo. J. Cerebral Blood Flow and Metabolism. 15:904-913.
47. Lancelot, E., Callebert, J., Lerouet, D., Revaud, M. L., Boulou, R. G., Plotkine, M. (1995): Role of the L-arginine-nitric oxide pathway in the basal hydroxyl radical production in the striatum of awake rats as measured by brain microdialisis. Neuroscience Letters. 202:21-24.